The Companion Diagnostics Market, 2013-2023 report provides an extensive study of the emerging market of companion diagnostics. The report differentiates personalised medicine diagnostics and companion diagnostics; we have separately defined these two closely associated markets and provided our estimates of the market size for each. The report covers various aspects, such as, advantages of personalised medicine over traditional medicine and the need for companion diagnostics.
One of the key objectives of this report is to understand the current state of the companion diagnostics market. This is done by analysing • Products currently available in the market and those under development, • Pharmaceutical and diagnostic companies active in the market, and • Deals and collaborations in the recent years
The market for companion diagnostics has also been evaluated regionally; this provides a greater clarity in the differing approaches various regions have towards personalised medicine and companion diagnostics. In parallel, we have also analysed the market for companion drugs that are associated with companion diagnostics.
The report provides market forecasts for the period 2012 - 2023. We have discussed, in detail, the key drivers behind the regional and global growth. The research, analysis and insights presented in this report include the sales of all companion diagnostic tests that are essential before prescription of any companion drug.All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified. Key Highlights1. The global companion diagnostics market is likely to achieve sales of USD 897 MM by 2018, growing at a compounded annual growth rate (CAGR) of 29.2% from 2012 to 2018.2. In 2011, 41.2% of the new molecular entities (NMEs) were approved with a pharmacogenomic biomarker by the FDA.3. The sales of marketed companion drugs generated estimated revenues of more than USD 22 BN in 2012, with six drugs achieving blockbuster status.4. In terms of value, 95.9% of the sales in the companion drugs market was contributed by drugs indicated for cancer.5. The overall companion drugs market is dominated by three leading companies – Roche Laboratories, Novartis and Pfizer. Together these companies accounted for 61.3% of the companion drugs market in 2012.6. There are several personalised medicine diagnostics in the market, with companion diagnostics constituting its subset. Companion diagnostics represented 10.1% of the personalised medicine diagnostics market in 2012.7. The pipeline for companion diagnostics is rich with most products being developed with the collaborative effort of pharmaceutical and diagnostics companies. Many start-ups diagnostic companies are also engaged in partnership with large pharmaceutical companies for developing companion diagnostic tests.8. The US was the largest market for companion diagnostics in 2012, accounting for 41.0% of the total market. 1. EXECUTIVE SUMMARY1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines1.4. Key Highlights1.4.1. Oncology is the Leading Indication for Companion Drugs1.4.2. Roche is One of the Most Active Companies in the Market1.4.3. Partnership is the Preferred Model for Companion Diagnostics Development1.4.4. US is the Largest Market for Companion Diagnostics1.4.5. Opportunities Outpace the Threats